233 related articles for article (PubMed ID: 30156363)
1. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
Xie C; Zhao H; Bao X; Fu H; Lou L
J Cell Mol Med; 2018 Nov; 22(11):5367-5377. PubMed ID: 30156363
[TBL] [Abstract][Full Text] [Related]
2. Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells.
Zhou N; Wang J; Li X; Zhao Y; Sun Y; Zou C
Cardiovasc Drugs Ther; 2016 Dec; 30(6):567-577. PubMed ID: 27838864
[TBL] [Abstract][Full Text] [Related]
3. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
4. Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO-R Agonist, in Healthy Individuals.
Zheng L; Liang MZ; Zeng XL; Li CZ; Zhang YF; Chen XY; Zhu X; Xiang AB
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):414-422. PubMed ID: 28544774
[TBL] [Abstract][Full Text] [Related]
5. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
7. Hetrombopag: First Approval.
Syed YY
Drugs; 2021 Sep; 81(13):1581-1585. PubMed ID: 34357499
[TBL] [Abstract][Full Text] [Related]
8. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Mei H; Liu X; Li Y; Zhou H; Feng Y; Gao G; Cheng P; Huang R; Yang L; Hu J; Hou M; Yao Y; Liu L; Wang Y; Wu D; Zhang L; Zheng C; Shen X; Hu Q; Liu J; Jin J; Luo J; Zeng Y; Gao S; Zhang X; Zhou X; Shi Q; Xia R; Xie X; Jiang Z; Gao L; Bai Y; Li Y; Xiong J; Li R; Zou J; Niu T; Yang R; Hu Y
J Hematol Oncol; 2021 Feb; 14(1):37. PubMed ID: 33632264
[TBL] [Abstract][Full Text] [Related]
10. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of an alternative splice variant of Mpl with a high affinity for TPO and its activation of ERK1/2 signaling.
Wang Q; Sun R; Wu L; Huang J; Wang P; Yuan H; Qiu F; Xu X; Wu D; Yu Y; Liu X; Zhang Q
Int J Biochem Cell Biol; 2013 Dec; 45(12):2852-63. PubMed ID: 24144576
[TBL] [Abstract][Full Text] [Related]
12. Novel chemical-structure TPOR agonist, TMEA, promotes megakaryocytes differentiation and thrombopoiesis via mTOR and ERK signalings.
Jiang X; Sun Y; Yang S; Wu Y; Wang L; Zou W; Jiang N; Chen J; Han Y; Huang C; Wu A; Zhang C; Wu J
Phytomedicine; 2023 Feb; 110():154637. PubMed ID: 36610353
[TBL] [Abstract][Full Text] [Related]
13. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
Fox NE; Lim J; Chen R; Geddis AE
Exp Hematol; 2010 May; 38(5):384-91. PubMed ID: 20188141
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL.
Nishino T; Miyaji K; Ishiwata N; Arai K; Yui M; Asai Y; Nakauchi H; Iwama A
Exp Hematol; 2009 Nov; 37(11):1364-1377.e4. PubMed ID: 19744539
[TBL] [Abstract][Full Text] [Related]
15. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis.
Tsutsumi N; Masoumi Z; James SC; Tucker JA; Winkelmann H; Grey W; Picton LK; Moss L; Wilson SC; Caveney NA; Jude KM; Gati C; Piehler J; Hitchcock IS; Garcia KC
Cell; 2023 Sep; 186(19):4189-4203.e22. PubMed ID: 37633268
[TBL] [Abstract][Full Text] [Related]
16. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
17. Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.
Lorenz V; Ramsey H; Liu ZJ; Italiano J; Hoffmeister K; Bihorel S; Mager D; Hu Z; Slayton WB; Kile BT; Sola-Visner M; Ferrer-Marin F
Thromb Haemost; 2017 Dec; 117(12):2322-2333. PubMed ID: 29212120
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.
Erickson-Miller CL; DeLorme E; Tian SS; Hopson CB; Stark K; Giampa L; Valoret EI; Duffy KJ; Luengo JL; Rosen J; Miller SG; Dillon SB; Lamb P
Exp Hematol; 2005 Jan; 33(1):85-93. PubMed ID: 15661401
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist.
Stasi R
Expert Opin Drug Discov; 2009 Jan; 4(1):85-93. PubMed ID: 23480339
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
